Skip to content
10-K

Annual Report

Actinium Pharmaceuticals, Inc. ATNM

0001213900-25-026371

← back to feed
Filed
Mar 31, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 28, 2025 31.2M sh
Shares Diluted FY 2024 · Dec 31, 2023 26.6M sh
Capex FY 2024 · Dec 31, 2023 $153K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$47.34M
Cash And Equivalents FY 2024 · Dec 31, 2023 $76.68M
Current Liabilities FY 2024 · Dec 31, 2023 $8.49M
Total Liabilities FY 2024 · Dec 31, 2023 $45.07M
Current Assets FY 2024 · Dec 31, 2023 $78.26M
Total Assets FY 2024 · Dec 31, 2023 $81.45M
Eps Diluted FY 2024 · Dec 31, 2023 −$1.83
Eps Basic FY 2024 · Dec 31, 2023 −$1.83
Sga Expense FY 2024 · Dec 31, 2023 $13.33M
Rd Expense FY 2024 · Dec 31, 2023 $38.67M
Net Income FY 2024 · Dec 31, 2023 −$48.82M
Operating Income FY 2024 · Dec 31, 2023 −$51.92M
Revenue FY 2024 · Dec 31, 2023 $81K
Stockholders Equity FY 2024 · Dec 31, 2022 $66.48M